Safety and immunogenicity of AGS-v PLUS, a mosquito saliva peptide vaccine against arboviral diseases: A randomized, double-blind, placebo-controlled Phase 1 trial
Titel:
Safety and immunogenicity of AGS-v PLUS, a mosquito saliva peptide vaccine against arboviral diseases: A randomized, double-blind, placebo-controlled Phase 1 trial
Auteur:
Friedman-Klabanoff, DeAnna J. Birkhold, Megan Short, Mara T. Wilson, Timothy R. Meneses, Claudio R. Lacsina, Joshua R. Oliveira, Fabiano Kamhawi, Shaden Valenzuela, Jesus G. Hunsberger, Sally Mateja, Allyson Stoloff, Gregory Pleguezuelos, Olga Memoli, Matthew J. Laurens, Matthew B.